Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer
716 TOMM20 overexpression enhances T-cell mitochondrial fitness and improves adoptive cell therapy in sarcoma
5 affiliations
- 11 Children`s Hospital and Institutes of Biomedical Sciences, State Key Laboratory of Genetic Engineering and School of Life Sciences, Fudan University, Shanghai, China
- 2Department of Epidemiology, Stanford Hospital and Clinics, Stanford, California, USA
- 31Thomas Jefferson University, Philadelphia, PA, USA
- 4Thomas Jefferson University, Philadelphia, Pennsylvania, USA
- 5Thomas Jefferson University, Philadelphia, PA, USA
Related
- Antibody Targeting Soluble NKG2D Ligand MIC Enhances Adoptive T-Cell Therapy in an NK Cell-Dependent Mechanism
- Ubiquitous Sirt1 overexpression is associated with preserved cardiac diastolic function and mitochondrial respiratory capacity in mice on a high-fat diet
- Overexpression of centromere-localized IFIT3 impairs mitochondrial function and disrupts cellular proliferation and cell cycle progression in down syndrome.
- ISAba1‐mediated crp‐osmC amplification enhances host‐associated fitness in Acinetobacter baumannii
- Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models
BibTeX
@article{lin2026tomm20,
title = {{716 TOMM20 overexpression enhances T-cell mitochondrial fitness and improves adoptive cell therapy in sarcoma}},
author = {Zhao Lin and Megan Roche and Diana Menezes and Ubaldo Martinez Outschoorn and Ranakul Islam and Victor Diaz-Barros},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
month = nov,
doi = {10.1136/jitc-2026-sitc2026.0716},
url = {https://doi.org/10.1136/jitc-2026-sitc2026.0716},
note = {CC BY},
}
RIS
TY - JOUR
TI - 716 TOMM20 overexpression enhances T-cell mitochondrial fitness and improves adoptive cell therapy in sarcoma
AU - Zhao Lin
AU - Megan Roche
AU - Diana Menezes
AU - Ubaldo Martinez Outschoorn
AU - Ranakul Islam
AU - Victor Diaz-Barros
PY - 2026
DA - 2026/11/05
JO - Journal for ImmunoTherapy of Cancer
DO - 10.1136/jitc-2026-sitc2026.0716
UR - https://doi.org/10.1136/jitc-2026-sitc2026.0716
SN - 2051-1426
ER -